Sosei Heptares
https://soseiheptares.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sosei Heptares
Boehringer Marches On In Mental Health With Sosei Heptares Pact
The family-owned German firm's legacy lies in the cardiometabolic space but it has been building a pipeline across a range of neuropsychiatric diseases. The collaboration with Sosei Heptares, which has been sealed with a upfront payment of €25m, will focus on schizophrenia.
Idorsia Asset Sell Off Continues But Future Still Up In The Air
A new outlicensing deal with Viatris will keep it afloat for now but Idorsia needs more time, money and R&D success to secure its long-term future.
News We're Watching: Layoffs At Illumina, Canary's Heart Sensor; SCS To Help Amputees; Samsung's Apnea Monitor
Medtech Insight's News We're Watching highlights a few medtech industry developments we are following: Illumina will lay off 111 people from its San Diego headquarters as it comes to grips with the impending Grail divestiture; a team of researchers have devised a way to use spinal cord stimulators to give amputees "feeling" in a leg that is no longer there; Samsung earns FDA de novo for sleep apnea monitor.
UK Biopharma Looks To Learn From Flagship Pioneering And Make ‘Bigger Leaps’
UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Heptares Therapeutics Limited
- Heptares Zurich
- G7 Therapeutics
- NewCo
- Sosei Co., Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice